Business Context and Reporting Period
Company: Iveda Solutions, Inc. (IVDA)
Filing Type: Form 8-K (Current Report)
Date of Report: February 9, 2026
Event Date: February 9, 2026 (Agreement); February 11, 2026 (Closing)
Context: The Company consummated a public offering of common stock, pre-funded warrants, and accompanying warrants to raise capital for general corporate purposes.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $2,000,000.
- Offering Price (Common Stock): $0.35 per share.
- Offering Price (Pre-Funded Warrants): $0.3499 per warrant.
- Shares Issued: 5,259,999 shares of Common Stock.
- Pre-Funded Warrants Issued: 454,287 (exercisable at $0.0001/share).
- Series X Warrants Issued: 11,428,572 (exercisable at $0.35/share; 2-year term).
- Placement Agent Fees: 7.0% cash fee ($140,000) plus 400,000 Placement Agent Warrants (exercise price $0.4375/share).
- Expense Reimbursement: $100,000 for legal expenses.
- Use of Proceeds: General corporate purposes, including R&D, debt repayment, working capital, and potential acquisitions.
Material Changes and Agreements
The filing details the entry into a Material Definitive Agreement (Item 1.01) regarding the securities offering. Key contractual changes include:
- Securities Purchase Agreement: Entered into with institutional investors on February 9, 2026.
- Engagement Agreement: Amended agreement with H.C. Wainwright & Co., LLC as the Placement Agent.
- Lock-Up Agreements: Directors and executive officers are restricted from selling or transferring shares for 30 days post-closing.
- Issuance Restrictions: The Company is restricted from issuing new equity or filing new registration statements for 12 months, and from Variable Rate Transactions for 6 months, subject to exceptions.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize net proceeds for software product R&D, repayment of existing indebtedness, working capital, capital expenditures, acquisitions, joint ventures, and stock repurchase programs.
Risks and Contingencies:
- Dilution: Significant issuance of warrants (Series X and Pre-Funded) creates potential future dilution.
- Liquidity Constraints: Proceeds are subject to deduction of fees and expenses; net cash available is less than the gross $2 million.
- Market Restrictions: The 12-month moratorium on new equity issuances limits immediate capital raising flexibility.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the $140,000 fee, $100,000 legal reimbursement, and other offering expenses.
- Confirm the total potential share count upon full exercise of all warrants (Series X, Pre-Funded, and Placement Agent).
- Review the specific "exceptions" to the 12-month issuance restriction in the Purchase Agreement (Exhibit 10.2).
- Check the Company's current debt levels to assess the impact of the stated intent to repay existing indebtedness.
- Monitor the 30-day lock-up expiration date for potential selling pressure from insiders.